by Rod Raynovich | Jan 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX,...
by Rod Raynovich | Jan 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down...
by Rod Raynovich | Jan 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the...
by Rod Raynovich | Jan 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Stay the Course for Now We will review our holdngs next week and rebalance if necessary. Overall it has been a good week with biotech indices up about 2%. Late January is always a good time for a correction but for now it is “don’t fight the FED,...
by Rod Raynovich | Jan 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics announced today that it signed a definitive merger agreement with IDEX Corp.(IEX) for $1.35 net cash to the seller subject to adjustment as provided in the merger agreement. The $1.35 price represents about a 58% premium over recent trading and a 69%...
by Rod Raynovich | Jan 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
We will be attending the JPMorgan Healthcare Conference in San Francisco next week looking for new ideas. Healthcare overall has been a laggard (up 1.87% vs 11.47% S&P for one year period) but subsectors such as diagnostics, tools, large cap drugs and selected...
by Rod Raynovich | Jan 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Diagnostics and Tools 2010 Original Price Price % Ret Recomm YrEnd’10 Abaxis ABAX 2/2/09 15 26.85 79 CardioV.Sys. CSII 11/5/10 7.15 11.66 63 Celera CRA 3/28/10 7 6.3 -10 Exact Sci EXAS 12/10/10 5.6 5.98 6.8 GenProbe GPRO 2/2/09 45 58.35 29.7 Illumina ILMN 2/2/09...
by Rod Raynovich | Dec 28, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The Life Science Sector (^BTK) Overall Has Outperformed Other Major Market Indices Over 10 Years As we approach year-end we can look back on a great year for all markets and outperformance for the Life Science sector. Benchmark ETF performance is as follows YTD: FBT...
by Rod Raynovich | Dec 27, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Three Value Stocks Off The Radar Screen At this time of the year, especially when the market has a bullish tone, small (IWM) and mid cap (MDY) stocks are likely to outperform-YTD they are up about 25%. MicroCaps also tend to do well in the Q4-Q1 time frame because...
by Rod Raynovich | Dec 17, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Biotech Outperforms Large Cap Pharma Biotechnology stocks were up today sparked by Intermune (ITMN $32.74)news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending their...
